A panel of experts has recommended that the FDA approve a drug that would be used before breast cancer patients undergo surgery.
The FDA approved Genentech's drug, called Perjeta, last year for patients in the later stages of breast cancer. Doctors say the drug might help make otherwise inoperable tumors a better fit for surgery. It may also help shrink large tumors to allow patients to conserve their breast during surgery, rather than have a full mastectomy.
In studies, though, the drug did not increase the number of women who opted for a lumpectomy rather than mastectomy.
The company estimates about 15,000 patients a year might be eligible.
Copyright 2013 KCBD. All rights reserved.